Bausch + Lomb Highlights Nearly 40 Scientific Studies at the 2025 Association for Research in Vision and Ophthalmology Annual Meeting

VAUGHAN, Ontario, May 1, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 39 scientific presentations during the Association for Research in Vision and Ophthalmology annual meeting, taking place in Salt Lake City, May 4-8, 2025.

The new scientific data will showcase findings from multiple studies across Bausch + Lomb’s extensive eye care portfolio, including a keynote presentation highlighting the mechanism of action for XIIDRA® (lifitegrast ophthalmic solution) 5%, which is indicated to treat the signs and symptoms of dry eye disease, and a poster presentation exploring the time course of early dry eye symptom relief.

Additional poster presentations will feature clinical insights evaluating early adoption and impact of MIEBO® (perfluorohexyloctane ophthalmic solution), which is indicated to treat the signs and symptoms of dry eye disease, Blink™ NutriTears® nutritional supplement for dry eyes, LUMIFY® Preservative Free redness reliever drops and patient-reported outcomes with Blink® Triple Care lubricating eye drops. Real-world assessments of Biotrue® Hydration Plus Multi-Purpose Solution and a multi-country assessment of Zenlens® ECHO™, a custom scleral contact lens technology designed to fit a wide variety of corneal shapes and sizes, will also be highlighted.

The latest optical bench data for our surgical portfolio will also be presented, with a focus on the enVista® intraocular lens (IOL) platform, our new refractive full range of vision LuxLife™ IOL and Stellaris Elite®, a combined phacoemulsification and vitrectomy system.

See below for the complete list of Bausch + Lomb scientific presentations:

Keynote Presentation
Wednesday, May 7

  • “The Mechanism of Action of Leucocyte Function-associated Antigen (LFA-1) Antagonist Lifitegrast in Dry Eye Disease.” Hamrah et al.
    11:30 a.m. – 11:45 a.m. MT; Ballroom C

Poster Presentations

  • “Variability Analysis of Intraocular Lenses Using Simulated Through-Focus Visual Acuity.” Alba-Bueno et al.  
  • “Mini-mono Vision and Trifocal lens – Objective Modeling of Different Approaches to Improve Visual Satisfaction.” Venkateswaran et al.
  • “Optical Performance and Refractive Outcomes of a Novel Monofocal Intraocular Lens with Intermediate Optimized Optics.” Hill C.
  • “Exploring New Methods to Predict Visual Acuity from Modulation Transfer Function in Intraocular Lenses.” Shamblin et al.
  • “Comparative Analysis of Phacoemulsification Efficiency: Insights into Two System Designs.” Papour et al.
  • “Comparison of Traction, Sphere of Influence, and Pulsatile Flow in-Vitro Vitrectomy Using 25ga 25,000 CPM Dual Action Vitrectomy Probes and 25ga 7,500 CPM Single Action Vitrectomy Probes.” Higgins et al. 
  • “Vitrectomy Flow Performance and Optimized System Settings for Retina Shaving with 25g, 25,000cpm Dual Action Vitrectomy Probes.” Heuer et al. 
  • “Evaluation of a Novel Tunable Intensity Wavelength Solid State Light (SSL) Source in Vitreoretinal (VR) Diseases for Enhanced Visualization and Instrumentation.” Chang E. 
  • “Aqueous Humor Outflow Improvement After Excimer Laser Trabeculostomy.” Strohmaier et al. 
  • “Robustness to Tilt and Decentration of Full Range of Vision Intraocular Lenses.” Millan et al.  
  • “Assessment of the Halo Caused by a New Full Range of Vision Intraocular Lens.” Vega et al.
  • “Evaluating the Impact of Tilt and Decentration on the Optical Performance of Monofocal and Enhanced Monofocal Intraocular Lenses.” Armengol et al.
  • “A Multi-Country Assessment of Clinical Experience With a Custom Scleral Lens System: Eyecare Practitioner Satisfaction.” Gidosh et al. 
  • “Real-World Assessment of a Novel Multi-Purpose Contact Lens Solution in Contact Lens Wearers Who Experience Contact Lens Dryness.” Reindel et al.  
  • “Real-World Assessment of a Novel Multi-Purpose Contact Lens Solution Among Excessive Contact Lens Wearers.” Schafer et al.  
  • “Real-World Assessment of a Novel Multi-Purpose Contact Lens Solution Among Hydrogen Peroxide Lens Care Users With Contact Lens Related Dryness.” Nguyen et al.
  • “Real-World Evaluation of Patient and Practitioner Satisfaction With a Novel Daily Disposable Silicone Hydrogel Toric Contact Lens: Study Summary and Early Experience.” Womack et al.  
  • “Development of an in Vitro Assay to Evaluate the Antioxidant Effects of Erythritol and Glycerin in a Packaging Formulation With Human Corneal Epithelial Cells.” Russell J et al.
  • “Optimization of E. Coli for Recovery of Acanthamoeba Cysts.” Domm W et al.
  • “Disinfection Efficacy of a Unique Multi-Purpose Solution Against Acanthamoeba Trophozoites.” Wheeler H et al.
  • “Evaluation of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution for the Treatment of Conjunctival Hyperemia.” McGee S et al.
  • “Assessing Healthcare Providers' Real-world Patient Education on Cosmetic/Aesthetic Product Impact on the Ocular Surface.” Cerenzia W et al.
  • “Conjunctival Hyperemia: A Multi-Country Assessment of Healthcare Professionals' Perspectives on the Treatment Landscape.” Koetting C et al.
  • “Analysis of Real-World Prescribing Patterns of Brimonidine Tartrate Ophthalmic Solution 0.025% for the Relief of Eye Redness.” Fain J et al.
  • “Patient-Reported Outcomes and Safety Assessments of a Novel Lipid-Containing Eye Drop Versus an Existing Lubricating Eye Drop.” Poteet J et al.
  • “Comparative Analysis of the Osmoprotective Effects of Over-the-Counter Dry Eye Formulations on Human Corneal Epithelial Cells.” Millard K et al.
  • “Antioxidant Effect of Magnesium Ascorbyl Phosphate (MAP) and a MAP-Containing Eye Drop in Human Corneal Epithelial Cells.” Kwon M et al.
  • “Comparative Analysis of the Antioxidant Effects of a Novel Over-the-Counter Dry Eye Drop on Human Corneal Epithelial Cells.” VanDerMeid K et al.
  • “Intervening in the Dry Eye Inflammatory Cycle With a Daily Oral Nutritional Supplement.” Periman L et al.
  • “The Effect of Lifitegrast 5.0% Solution on Clinical Signs and Biomarkers in Dry Eye Disease: A Prospective, Multicenter Study.” Karpecki P et al.
  • “Real-World Experience With Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: a Provider Survey.” Cavet M et al.
  • “Early Symptom Relief with Lifitegrast Ophthalmic Solution, 5.0% in Patients With Dry Eye Disease: a Post-Hoc Analysis of Two Randomized Clinical Trials.” Nijm L et al.
  • “The Impact of a Single Drop of Perfluorohexyloctane Ophthalmic Solution (MIEBO®) has on Biometry Measurements and Intraocular Lens Calculations.” Karpuk K et al.
  • “Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease and Cataract: Post Hoc Analysis of Pooled Data From Pivotal Trials.” Sheppard J et al.
  • “Early Adoption and Utilization of Perfluorohexyloctane Ophthalmic Solution for Dry Eye Disease.” Shen Lee B et al.
  •  “Effect of the Dry Eye Drop Perfluorohexyloctane and Comparator Semifluorinated Alkanes on the Evaporation Rate of Saline in Vitro.” Borchman D et al.
  • “Investigating the Effect of Reducing the Signs and Symptoms of Lid Wiper Epitheliopathy in Dry Eye Subjects with Perfluorohexyloctane.” Lievens C et al.
  • “Early Symptom Relief and Satisfaction With Perfluorohexyloctane Ophthalmic Solution in Dry Eye Disease: a Prospective, Open-Label, Multicenter Study.” Kannarr S et al.

###

Important Safety Information for XIIDRA

Indication
Xiidra®(lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for Xiidra.

Important Safety Information for MIEBO

INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information for Zenlens ECHO
WARNINGS:

Patients should be advised of the following warnings pertaining to contact lens wear:

  • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eyecare practitioner’s directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.
  • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping.
  • Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight.
  • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
  • If a patient experiences eye discomfort, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner.

CONTRAINDICATIONS:
Do not use when any of the following conditions exist:

  • Acute or subacute inflammation or infection of the anterior chamber of the eye
  • Any eye disease, injury or abnormality, other than keratoconus, PMD, that affects the cornea, conjunctiva or eyelids
  • Severe insufficiency of lacrimal secretion (dry eye)
  • Corneal hypoesthesia (reduced sensitivity), if not aphakic
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions
  • Allergy to any ingredient in a solution which is to be used to care for contact lenses
  • Any active corneal infection (bacterial, fungal or viral)
  • Red or irritated eyes

ADVERSE EFFECTS:
The following problems may occur with the use of contact lenses:

  • Eyes stinging, burning, itching, irritation or other eye pain
  • Comfort is less than when the lens was first placed on the eye
  • Feeling of something in the eye such as a foreign body, scratched area
  • Excessive watering (tearing) of the eye
  • Unusual eye secretions Redness of the eyes
  • Reduced sharpness of vision (poor visual acuity)
  • Blurred vision, rainbows, or halos around objects
  • Sensitivity to light (photophobia)
  • Dry eyes

NUTRITEARS is a trademark of OmniActive Health Technologies Ltd., used under license.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook , Instagram , LinkedIn , X and YouTube .

Media Contact:
Caryn Marshall
[email protected]
(908) 493-1381

© 2025 Bausch + Lomb.
MTB.0201.USA.25

Back to Press Releases